Emcure Pharmaceuticals has launched Poviztra, a second brand of Novo Nordisk’s semaglutide injection for weight management in India. It will be priced at Rs 8,790 per month, 15-20% lower than Novo Nordisk’s Wegovy. Emcure will exclusively distribute and commercialise Poviztra, with plans to roll it out in Tier I, II, and III cities. The drug is indicated for chronic weight management in adults